Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Feb;77(2):122–127. doi: 10.1136/hrt.77.2.122

Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.

O D Pedersen 1, J Gram 1, J Jespersen 1
PMCID: PMC484659  PMID: 9068393

Abstract

OBJECTIVE: To determine whether there was a relation between plasma resistance to activated protein C and the coagulation activation induced during thrombolysis with 100 mg alteplase in 25 patients with acute ischaemic heart disease. METHODS: Blood samples were collected before (t = 0 h), during (t = 2.25 h), and after (t = 4 h, t = 12 h, and t = 24 h) thrombolysis to examine the relation between baseline activated protein C resistance ratio and markers of coagulation activation-that is, thrombinantithrombin III-complexes and prothrombin fragment 1 + 2 generated during thrombolysis. RESULTS: There was a negative correlation between activated protein C resistance ratio and area under the curve of thrombin-antithrombin III-complexes (rs = - 0.60; P < 0.003) and there was a trend to a negative correlation between activated protein C resistance ratio and area under the curve of prothrombin fragment 1 + 2 (rs = - 0.37; P = 0.07). This accorded with the negative correlation between activated protein C resistance ratio and the peak value of thrombin-antithrombin III-complexes (rs = - 0.55; P < 0.005) and between activated protein C resistance ratio and the peak value of prothrombin fragment 1 + 2 (rs = - 0.42; P < 0.04). Components of the protein C/S system or known inhibitors of activated protein C may influence the activated protein C resistance ratio. There were no associations between the activated protein C resistance ratio and protein C, protein C inhibitor, or plasminogen activator inhibitor type-1, whereas there was a trend to a negative correlation between activated protein C resistance ratio and protein S. CONCLUSIONS: The results indicate that plasma resistance to activated protein C may be one of the main mechanisms regulating the activation of coagulation induced by thrombolysis. This study suggests that it may be possible to single out individuals with a high risk of reocclusion before the start of thrombolytic therapy.

Full text

PDF
122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreotti F., Kluft C., Hackett D. R., Davies G. J., Maseri A. Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator. Lancet. 1993 Oct 9;342(8876):937–938. doi: 10.1016/0140-6736(93)91991-t. [DOI] [PubMed] [Google Scholar]
  2. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  3. Boyer C., Rothschild C., Wolf M., Amiral J., Meyer D., Larrieu M. J. A new method for the estimation of protein C by ELISA. Thromb Res. 1984 Dec 15;36(6):579–589. doi: 10.1016/0049-3848(84)90197-x. [DOI] [PubMed] [Google Scholar]
  4. Collen D. Towards improved thrombolytic therapy. Lancet. 1993 Jul 3;342(8862):34–36. doi: 10.1016/0140-6736(93)91888-s. [DOI] [PubMed] [Google Scholar]
  5. Emmerich J., Poirier O., Evans A., Marques-Vidal P., Arveiler D., Luc G., Aiach M., Cambien F. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet. 1995 Feb 4;345(8945):321–321. [PubMed] [Google Scholar]
  6. Esmon C. T. Protein-C: biochemistry, physiology, and clinical implications. Blood. 1983 Dec;62(6):1155–1158. [PubMed] [Google Scholar]
  7. Fay W. P., Owen W. G. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C. Biochemistry. 1989 Jul 11;28(14):5773–5778. doi: 10.1021/bi00440a011. [DOI] [PubMed] [Google Scholar]
  8. Galvani M., Abendschein D. R., Ferrini D., Ottani F., Rusticali F., Eisenberg P. R. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol. 1994 Nov 15;24(6):1445–1452. doi: 10.1016/0735-1097(94)90138-4. [DOI] [PubMed] [Google Scholar]
  9. Gram J., Munkvad S., Leebeek F. W., Kluft C., Jespersen J. Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator. Coron Artery Dis. 1993 Apr;4(4):371–377. doi: 10.1097/00019501-199304000-00009. [DOI] [PubMed] [Google Scholar]
  10. Greengard J. S., Eichinger S., Griffin J. H., Bauer K. A. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med. 1994 Dec 8;331(23):1559–1562. doi: 10.1056/NEJM199412083312305. [DOI] [PubMed] [Google Scholar]
  11. Gruber A., Pál A., Kiss R. G., Sas G., Griffin J. H. Generation of activated protein C during thrombolysis. Lancet. 1993 Nov 20;342(8882):1275–1276. doi: 10.1016/0140-6736(93)92364-y. [DOI] [PubMed] [Google Scholar]
  12. Gulba D. C., Barthels M., Westhoff-Bleck M., Jost S., Rafflenbeul W., Daniel W. G., Hecker H., Lichtlen P. R. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation. 1991 Mar;83(3):937–944. doi: 10.1161/01.cir.83.3.937. [DOI] [PubMed] [Google Scholar]
  13. Jespersen J., Nielsen M. T. Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest. 1989;28(2):82–86. doi: 10.1159/000293521. [DOI] [PubMed] [Google Scholar]
  14. Matthews J. N., Altman D. G., Campbell M. J., Royston P. Analysis of serial measurements in medical research. BMJ. 1990 Jan 27;300(6719):230–235. doi: 10.1136/bmj.300.6719.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Munkvad S., Gram J., Jespersen J. Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study. Scand J Clin Lab Invest. 1991 Nov;51(7):581–590. doi: 10.1080/00365519109104568. [DOI] [PubMed] [Google Scholar]
  16. Rapold H. J., Grimaudo V., Declerck P. J., Kruithof E. K., Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. Blood. 1991 Sep 15;78(6):1490–1495. [PubMed] [Google Scholar]
  17. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  18. Seifried E., Tanswell P. Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemost. 1987 Oct 28;58(3):921–926. [PubMed] [Google Scholar]
  19. Sidelmann J., Gram J., Pedersen O. D., Jespersen J. Influence of plasma platelets on activated protein C resistance assay. Thromb Haemost. 1995 Sep;74(3):993–994. [PubMed] [Google Scholar]
  20. Suzuki K., Deyashiki Y., Nishioka J., Toma K. Protein C inhibitor: structure and function. Thromb Haemost. 1989 Jun 30;61(3):337–342. [PubMed] [Google Scholar]
  21. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  22. Weaver W. D., Hartmann J. R., Anderson J. L., Reddy P. S., Sobolski J. C., Sasahara A. A. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group. J Am Coll Cardiol. 1994 Nov 1;24(5):1242–1248. doi: 10.1016/0735-1097(94)90105-8. [DOI] [PubMed] [Google Scholar]
  23. Zöller B., Svensson P. J., He X., Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994 Dec;94(6):2521–2524. doi: 10.1172/JCI117623. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES